Heart failure & cardiomyopathiesRandomised controlled trial
Cardio-Microcurrent Device Treatment for Heart Failure with Reduced Ejection Fraction: Results from the C-MIC II Open-Label Randomized Controlled Trial
- Randomised controlled trial
- open-label
Authors' conclusion
In patients with non-ischaemic chronic heart failure with reduced ejection fraction, the C-MIC device compared with control improved LVEF, symptoms, functional capacity and quality of life.
Study context
- Population
- Ambulatory patients with non-ischaemic dilated cardiomyopathy, left ventricular ejection fraction (LVEF) 25% to 35%, New York Heart Association (NYHA) class III–IV65 in modified ITT analysis
- Participants
- 70 patients
- Comparison
- C-MIC vs Control
- C-MICn = 32
- Controln = 33reference
- Primary endpoint
- Change in LVEF
- Follow-up
- 6 months
Primary result
As reported in the abstract
Mean difference
5.1 %
95% CI 3.1–7.1
P < 0.001
C-MIC vs Control
mean difference 5.1 % (95% CI 3.1–7.1); P < 0.001
Secondary outcomes
| Outcome | risk difference (%) (95% CI) | P value | |
|---|---|---|---|
| Improvement in ≥1 NYHA class | 68.9 (50.6–87.2) | P < 0.001 | |
| Increase of ≥5 points in KCCQ-OSS | 60.0 (42.3–77.6) | P < 0.001 | |
| Increase of ≥30% in 6MWD | 38.3 (14.4–62.2) | P < 0.002 | |
| −50050100Difference, % (linear scale) |
Original publication
Cardio-Microcurrent Device Treatment for Heart Failure with Reduced Ejection Fraction: Results from the C-MIC II Open-Label Randomized Controlled Trial. Eur J Heart Fail. Published 15 July 2025. doi:10.1002/ejhf.3763
Summarised from the published abstract; every number is checked against it